MedTrace Logo

Humira in Rheumatoid Arthritis - Do Bone Erosions Heal?

NCT00696059 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 52

Last updated 2008-06-12

No results posted yet for this study

Summary

Studies on tumor necrosis factor alpha antagonist (anti-TNF) therapy in rheumatoid arthritis (RA) patients have found that erosive damage may "heal" in some RA patients treated with anti-TNF. Repeated examinations of adalimumab (Humira) treated RA patients, using computed tomography (CT), magnetic resonance imaging (MRI), ultrasonography (US) and radiography will allow detailed assessment of the extent of bone repair/healing during adalimumab (Humira) therapy.

Conditions

Interventions

DRUG

Adalimumab (Humira)

Adalimumab (Humira) 40 mg subcutaneously every other week

Sponsors & Collaborators

  • Abbott

    collaborator INDUSTRY

  • Hvidovre University Hospital

    lead OTHER

Principal Investigators

  • Mikkel Østergaard, Professor · Department of Rheumatology, Hvidovre University Hospital

  • Uffe Møller Døhn, M.D · Department of Rheumatology, Hvidovre University Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-08-31
Primary Completion
2007-07-31
Completion
2007-07-31

Countries

  • Denmark

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00696059 on ClinicalTrials.gov